Physician profile
Vincent A Codella
NPI 1134111248
$9,299.09
in general payments reported to CMS, 2019-2025
47 companies · $1,033 in 2025
The $1,033 reported for 2025 was more than what 86% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,055 · 2020: $1,824 · 2021: $1,380 · 2022: $947 · 2023: $1,062 · 2024: $998 · 2025: $1,033.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,094.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,093.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $1,316.23 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Novo Nordisk INC | $1,258.47 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Boehringer Ingelheim Pharmaceuticals, INC. | $803.70 | 2019-2025 | Jardiance |
| Lilly USA, LLC | $796.49 | 2019-2025 | Mounjaro, Zepbound |
| Merck Sharp & Dohme LLC | $540.77 | 2019-2025 | Lagevrio, Segluromet, Steglatro |
| Glaxosmithkline, LLC. | $460.62 | 2019-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Pfizer INC. | $438.08 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $413.88 | 2019-2025 | Spravato, Xarelto |
| Azurity Pharmaceuticals, INC. | $220.68 | 2023-2025 | Edarbi, Edarbyclor, Horizant |
| Otsuka America Pharmaceutical, INC. | $201.40 | 2021-2025 | Rexulti |
| Amarin Pharma, INC. | $197.52 | 2019-2020 | |
| Kowa Pharmaceuticals America, INC. | $196.12 | 2019-2021 | |
| Arbor Pharmaceuticals, INC. | $185.39 | 2019-2022 | |
| Abbvie INC. | $179.88 | 2021-2025 | Vraylar |
| Tepha INC | $175.81 | 2019 |
Show all 47 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vincent Codella listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.